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Abstract
Overactive bladder is a condition where the bladder muscles 
contract before the bladder is full, causing the urge to urinate. The 
standard first line medication for overactive bladder is solifenacin, 
and mirabegron serves as an alternative option. Solifenacin is an 
anticholinergic medication that is associated with a wide range of 
undesirable side effects. Therefore, this review analyzes the use of 
a combination of solifenacin and mirabegron, compared to 
monotherapy with solifenacin, for symptom management in 
patients suffering from moderate to severe overactive bladder. 
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Overactive Bladder
Overview:
● Condition involves involuntary leakage of urine 
● Consists of stress urinary incontinence, overflow incontinence 
and urge incontinence 
● Affects 17% of adults in the United States and Europe 
Symptoms:
● Urinary urgency, urinary frequency, nocturia
● Can significantly reduce quality of life, leading to higher levels of 
anxiety and depression, reduced general health status and poorer 
sleep quality 
Treatment:
● Conservative treatment includes weight loss, fluid reduction, 
bladder training, pelvic floor muscle exercises or electrical 
stimulation of the posterior tibial nerve.
● Pharmacologic treatment with anticholinergics, beta- adrenergic 
agonists, OnabotulinumtoxinA or intravaginal estrogen 
● First line: Solifenacin, an antimuscarinic drug, and mirabegron, a 
beta- adrenergic agonist 
Introduction
Methods
Performed in November 2019 using:
● PubMed
● Academic Search Ultimate
● Google Scholar  
Search terms: “urinary incontinence” AND “mirabegron” AND 
“solifenacin”
Inclusion Criteria:
1.Publish date within last 5 years 
2.Randomized control trial or clinical trial
Exclusion Criteria: 
1.Systematic review or meta-analysis 
2.Studies involving trials with animals and not humans 
3.Studies involving humans outside of adult age range 
6/7 studies found the greatest reduction of symptoms with 
solifenacin and mirabegron when compared to solifenacin only, 
mirabegron only, or placebo. 
Strengths:
● All studies based on randomized control trial with a double-blind 
study design à prevents research outcomes from being affected 
by placebo effect or observer bias 
● 6/7 studies required participants to have symptoms of overactive 
bladder for at least 3 months
● Recruitment methods 
Limitations: 
● Small sample sizes 
● Short study durations with no long term follow up 
Future Research: 
● Studies showing efficacy and tolerability for a longer duration 
and larger population is needed to improve the validity of the 
results
Discussion Results 
Mirabegron and Solifenacin in the Treatment 
of Overactive Bladder
Since only one study conducted to this date has taken place over 12 
months, more follow up research should be conducted to evaluate 
the long-term efficacy and tolerability of the combination of 
mirabegron and solifenacin in the treatment of overactive bladder. 
In addition, future studies should aim to include a greater number 
of male participants, since majority of the studies discussed above 
consisted of mainly female participants. The prevalence of the 
condition is similar in both males and females, and therefore studies 
should look at the effectiveness of treatment regimen equally 
across both sexes. Trials with a larger sample size, with different 
racial groups, cultural groups, and co-morbidities should also be 
conducted. Although some of these seven studies had areas with 
weakness, the results from the studies as a whole may support the 
use of solifenacin and mirabegron together to treat overactive 
bladder that does not respond to monotherapy. Future research is 
warranted. 
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1 RCT 1306 867 F
439 M
18 or older ≥3 months 12 weeks solifenacin, 
mirabegron or 
placebo 
2 RCT 1887 1434 F
453 M
18 or older ≥3 months 12 weeks solifenacin 5 
mg 
3 RCT 2174 1757 F
353 M








≥3 months 112 months mirabegron, 
solifenacin, or 
placebo 
5 RCT 3527 2716 F
811 M
18 or older NA 18 weeks mirabegron, 
solifenacin, or 
placebo 
6 RCT 239 NA Average age: 
71.2
≥3 months 6 weeks solifenacin, 
mirabegron or 
placebo 




Table 1: Comparison of study designs for Mirabegron and Solifenacin vs. Monotherapy
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